JNJ

Johnson & Johnson Q1 2008 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the fiscal first quarter ended March 30, 2008. Johnson & Johnson operates in three primary segments: Consumer, Pharmaceutical, and Medical Devices & Diagnostics. The company reported strong overall growth driven by favorable currency impacts and operational gains in the Consumer and Medical Devices segments, offset by patent expirations and generic competition in the Pharmaceutical segment.

Key Financial Metrics

Note: Q1 2007 results included a one-time $807 million in-process research and development (IPR&D) charge related to the acquisition of Conor Medsystems, which significantly depressed prior-year earnings.

Material Changes vs. Prior Period

• Revenue Growth: Worldwide sales increased 7.7%, with a 2.6% operational increase and a 5.1% positive impact from currency. International sales grew 13.7% (2.4% operational, 11.3% currency).
• Profitability Surge: Net earnings rose 39.8% year-over-year. This increase is largely attributable to the absence of the $807 million IPR&D charge recorded in Q1 2007, alongside improved operating margins.
• Segment Performance:
  • Consumer: Sales up 16.2% (9.9% operational). Driven by OTC Pharmaceuticals (Zyrtec launch) and Baby Care.
  • Pharmaceutical: Sales up 3.3% but operational sales declined 0.6%. Declines in Risperdal (generic competition) and Procrit were offset by growth in Remicade and Concerta.
  • Medical Devices: Sales up 7.2% (1.4% operational). Cordis franchise declined 15.2% operationally due to drug-eluting stent market contraction and competition.
• Liquidity: Cash and cash equivalents increased by $5.9 billion to $10.5 billion, primarily due to strong operating cash generation and reduced acquisition activity.

Guidance, Outlook, and Risks

• Dividends: The Board declared a quarterly dividend of $0.460 per share (a 10.8% increase), marking the 46th consecutive year of dividend increases.
• Share Repurchases: The company repurchased 22.7 million shares for approximately $1.4 billion during the quarter under its ongoing program.
• Patent Expirations: Significant risks remain regarding the expiration of patents for key products:
  • Risperdal: U.S. patent expired Dec 2007; pediatric exclusivity extends protection to June 2008. Generic competition is expected to significantly reduce sales.
  • Topamax: U.S. patent expires September 2008. Pediatric extension application filed.
• Legal Proceedings: The company faces numerous product liability suits (e.g., Ortho Evra, Risperdal, Duragesic) and patent litigation (e.g., Cordis stents vs. Boston Scientific/Medtronic). The company believes accrued liabilities are sufficient but notes outcomes are uncertain. Regulatory investigations regarding marketing practices (e.g., Risperdal, Topamax, Procrit) and the Foreign Corrupt Practices Act (FCPA) are ongoing.
• Restructuring: A $745 million restructuring program initiated in Q3 2007 continues, targeting cost reductions to offset generic competition and market challenges.

Investor Verification Checklist

• Generic Impact: Verify the actual sales erosion rates for Risperdal and Topamax as their U.S. patent protections expire in mid-to-late 2008.
• Stent Market: Monitor the recovery or continued decline of the Cordis franchise amidst the drug-eluting stent market contraction and patent litigation outcomes.
• Legal Reserves: Review the adequacy of accrued liabilities for product liability claims, particularly regarding Ortho Evra and Risperdal, given the high volume of claimants.
• Regulatory Scrutiny: Track the status of government investigations into marketing practices (Risperdal, Topamax, Procrit) and potential fines or settlements.
• Currency Sensitivity: Assess the sustainability of revenue growth given that 5.1% of Q1 2008 sales growth was driven by favorable currency fluctuations.